Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population-based cohort study.

Yao-Chun HsuYi-Hsian LinTeng-Yu LeeMindie H Nguyen Cheng-Hao TsengHsiu J HoFeng-Yu KaoJaw-Town LinChen-Yi WuChun-Ying Wu

Published in: Alimentary pharmacology & therapeutics (2023)

Severe flares with hepatic decompensation were observed in 1%-2% of patients with CHB after stopping NUC therapy in daily practice. Risk factors included older age, cirrhosis, portal hypertension and male sex. Our findings argue against NUC cessation as part of routine clinical care.

Keyphrases

risk factors
healthcare
early onset
physical activity
blood pressure
quality improvement
primary care
palliative care
stem cells
molecular docking
clinical practice
chronic pain